Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume – Time to Buy?

Upstream Bio, Inc. (NASDAQ:UPB) saw an uptick in trading volume on Friday . 2,234,547 shares were traded during trading, an increase of 114% from the previous session’s volume of 1,042,253 shares.The stock last traded at $9.8690 and had previously closed at $12.80.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Evercore began coverage on Upstream Bio in a research report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Mizuho raised Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Lifesci Capital began coverage on Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Stock Down 31.6%

The company has a market cap of $472.85 million, a price-to-earnings ratio of -4.65 and a beta of 1.90. The business has a 50-day simple moving average of $28.25 and a two-hundred day simple moving average of $23.24.

Hedge Funds Weigh In On Upstream Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC grew its holdings in Upstream Bio by 6.3% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock valued at $26,786,000 after buying an additional 144,216 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Upstream Bio by 57.5% in the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock valued at $7,101,000 after acquiring an additional 235,958 shares during the period. Norges Bank acquired a new stake in shares of Upstream Bio in the second quarter worth $10,650,000. Virtus Investment Advisers LLC acquired a new stake in shares of Upstream Bio in the second quarter worth $89,000. Finally, Police & Firemen s Retirement System of New Jersey increased its position in Upstream Bio by 133.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,833 shares of the company’s stock worth $86,000 after acquiring an additional 4,483 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.